Medindia
Personalized health information & news! Register
Medindia » Respiratory Disease News

App Diagnoses Respiratory Diseases Through a Cough Into a Smartphone

by Shirley Johanna on April 11, 2016 at 11:17 AM

An app that can diagnose respiratory diseases has been developed by an Australia-based digital health solution provider. The app diagnoses diseases like pneumonia, croup, and asthma with high accuracy through a cough into a smartphone.


The app ResApp has been developed by Perth-based ResApp Health. A recent clinical study of 524 pediatric patients at the West Australian city's Joondalup Health Campus and Princess Margaret Hospital found that the smartphone-based system can achieve an overall accuracy of 89 percent, the West Australian reported.

‘The smartphone-based app �ResApp� can detect respiratory illnesses with an overall accuracy of 89 percent. ’

ResApp has been developing machine-learning algorithms that will automatically determine which respiratory condition a patient might have, including pneumonia, asthma, bronchiolitis, and COPD -- an umbrella term used to describe progressive lung diseases.

The company released data from this trial previously in November, but that data set included fewer patients.

The larger group is now starting to show ResApp's effectiveness in diagnosing less common conditions.

"We are pleased to report again high levels of accuracy on a dataset that is more than 50 percent larger than the previously used dataset," Tony Keating, CEO and managing director of ResApp, said in a statement.

"These updated results reaffirm the algorithm's clinical accuracy right before we enter the pivotal studies needed for our upcoming premarket submission to the US Food and Drug Administration," he added.

Also, these preliminary results for the separation of bacterial and atypical pneumonia from viral pneumonia are very exciting as they demonstrate the power of ResApp's algorithm in supporting clinicians in making critical decisions for patient treatment," Keating noted.

Source: IANS

View Non AMP Site | Back to top ↑